A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial-Reference-Cited by-同舟云学术

A study of second-line irinotecan plus cisplatin vs. irinotecan alone in platinum-naïve patients with early relapse of gastric cancer refractory to adjuvant S-1 monotherapy: exploratory subgroup analysis of the randomized phase III TRICS trial

Published:2019-02-26 Issue:5 Volume:83 Page:867-874
ISSN:0344-5704
Container-title:Cancer Chemotherapy and Pharmacology
language:en
Short-container-title:Cancer Chemother Pharmacol

Author:

Nishikawa Kazuhiro^ORCID,Murotani Kenta,Fujitani Kazumasa,Inagaki Hitoshi,Akamaru Yusuke,Tokunaga Shinya,Takagi Masakazu,Tamura Shigeyuki,Sugimoto Naotoshi,Shigematsu Tadashi,Yoshikawa Takaki,Ishiguro Tohru,Nakamura Masato,Hasegawa Hiroko,Morita Satoshi,Miyashita Yumi,Tsuburaya Akira,Sakamoto Junichi,Tsujinaka Toshimasa

Publisher

Springer Science and Business Media LLC

Subject

Pharmacology (medical),Cancer Research,Pharmacology,Toxicology,Oncology

Link

http://link.springer.com/article/10.1007/s00280-019-03802-9/fulltext.html

Reference17 articles.

1. Sakuramoto S, Sasako M, Yamaguchi T, Kinoshita T, Furukawa H, Yamaguchi T et al (2007) Adjuvant chemotherapy for gastric cancer with S-1, an oral fluoropyrimidine. N Engl J Med 357:1810–1820

2. Sasako M, Sakuramoto S, Katai H, Kinoshita T, Furukawa H, Yamaguchi T et al (2011) Five-year outcomes of a randomized phase III trial comparing adjuvant chemotherapy with S-1 versus surgery alone in stage II or III gastric cancer. J Clin Oncol 29:4387–4393

3. Ito S, Ohashi Y, Sasako M (2018) Survival after recurrence in patients with gastric cancer who receive S-1 adjuvant chemotherapy: exploratory analysis of the ACTS-GC trial. BMC Cancer 18(1):449. [Epub ahead of print]

4. Hironaka S, Ueda S, Yasui H, Nishina T, Tsuda M, Tsumura T et al (2013) Randomized, open-label, phase III study comparing irinotecan with paclitaxel in patients with advanced gastric cancer without severe peritoneal metastasis after failure of prior combination chemotherapy using fluoropyrimidine plus platinum: WJOG 4007 trial. J Clin Oncol 31:4438–4444

5. Higuchi K, Tanabe S, Shimada K, Hosaka H, Sasaki E, Nakayama N et al (2014) Biweekly irinotecan plus cisplatin versus irinotecan alone as second-line treatment for advanced gastric cancer: a randomised phase III trial (TCOG GI-0801/BIRIP trial). Eur J Cancer 50:1437–1445

Cited by 4 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Relationships among microbiota, gastric cancer, and immunotherapy;Frontiers in Microbiology;2022-09-12

2. Cisplatin Plus Capecitabine After Adjuvant S-1 in Metastatic Gastric Cancer: A Phase II T-CORE1102 Trial;Anticancer Research;2022-03-28

3. Taxane‐based versus platinum‐based chemotherapy in early recurrent gastric cancer after radical surgery with S‐1 adjuvant chemotherapy: A multi‐institutional retrospective analysis;Asia-Pacific Journal of Clinical Oncology;2021-07-07

4. Comparison of effects of UGT1A1*6 and UGT1A1*28 on irinotecan-induced adverse reactions in the Japanese population: analysis of the Biobank Japan Project;Journal of Human Genetics;2019-10-04